Update on the optimal use of bortezomib in the treatment of multiple myeloma
Meera Mohan, Aasiya Matin, Faith E Davies Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA Abstract: The proteasome inhibitor (PI) “bortezomib” has now been in routine clinical practice for over a decade. It is now considered an importa...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2017-03-01
|
| Saila: | Cancer Management and Research |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.dovepress.com/update-on-the-optimal-use-of-bortezomib-in-the-treatment-of-multiple-m-peer-reviewed-article-CMAR |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|